Epstein-Barr Virus-associated Cancers: Aetiology and Treatment

Herpes

Volumn 10, Issue 3, 2003, Pages 78-82

  Lopes, Victor ^a   Young, Lawrence S ^a   Murray, Paul G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

B cell lymphomas; Epstein Barr virus; Gene therapy; Immunotherapy; Infectious mononucleosis; Lymphoproliferative disease; T cell lymphomas; Undifferentiated nasopharyngeal carcinoma; Vaccination

Indexed keywords

EPSTEIN BARR VIRUS VACCINE; HYDROXYUREA;

ADOPTIVE IMMUNOTHERAPY; CANCER; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; EPITHELIUM; EPSTEIN BARR VIRUS; GENE EXPRESSION; HOST CELL; HUMAN; IMMUNE RESPONSE; LYMPHOID TISSUE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

GENE THERAPY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOTHERAPY; LYMPHOMA; NASOPHARYNGEAL NEOPLASMS; VIRAL VACCINES;

HUMAN HERPESVIRUS 4;

EID: 0347285462     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Andersson J. An overview of Epstein-Barr virus: from discovery to future directions for treatment and prevention. Herpes 1999;7:76-82.
2. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984;310:207-211.
3. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985;35:35-42.
4. Kieff E. & Rickinson A. Epstein Barr Virus and its replication. In: Fields Virology, Chapter 74, 4th edn. (Fields BN, Howley PM, eds). Philadelphia, Lippincott-Williams & Wilkins 2001; pp2511-2574.
5. Wang F, Gregory CD, Rowe M, Rickinson AB, Wang D, Birkenbach M et al. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A 1987;84:3452-3456.
6. Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B. The protooncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 1999;73:4481-4484.
7. Sakai T, Taniguchi Y, Tamura K, Minoguchi S, Fukuhara T, Strobl LJ et al. Functional replacement of the intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2. J Virol 1998;72:6034-6039.
8. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A 1994;91:7568-7572.
9. Robertson ES. The Epstein-Barr virus EBNA 3 protein family as regulators of transcription. In: Epstein-Barr Virus Report 4 1997; pp143-150. Pub. Maney for Leeds Medical Information. U.K.
10. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-560.
11. Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998;16:1731-1742.
12. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999;274:16085-16096.
13. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 1995;2:155-166.
14. Neri A, Barriga F, Inghirami G, Knowles DM, Neequaye J, Magrath IT et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 1991;77:1092-1095.
15. Razzouk BI, Srinivas S, Sample CE, Singh V, Sixbey JW. Epstein-Barr Virus DNA recombination and loss in sporadic Burkitt's lymphoma. Infect Dis 1996;173:529-535.
16. Klein G. The relationship of the virus to nasopharyngeal carcinoma. In: The Epstein-Barr Virus (Epstein MA, Achong BG, eds). Berlin, Springer-Verlag 1979; pp339-350.
17. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47:883-889.
18. Yu MC, Ho JH, Lai SH, Henderson BE. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res 1986;46:956-961.
19. Hsu JL, Glaser SL. Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000;34:27-53.
20. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-1085.
21. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989;74:810-816.
22. Flavell KJ, Murray PG. Hodgkin's disease and the Epstein-Barr virus. Mol Pathol 2000;53:262-269.
23. Neidobitek GYLS. Epstein-Barr virus and non-Hodgkin's lymphomas. In: The Non-Hodgkin's Lymphomas, 2nd edn (Magrath IT, ed). London, Arnold 1997; pp309-329.
24. Brink AA, ten Berge RL, van den Brule AJ, Willemze R, Chott A, Meijer CJ. Epstein-Barr virus is present in neoplastic cytotoxic T cells in extranodal, and predominantly in B cells in nodal T non-Hodgkin lymphomas. J Pathol 2000;191:400-406.
25. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
26. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A et al. Treatment of Epstein-Barr-virus-positive posttransplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436-442.
27. Rooney CM, Roskrow MA, Smith CA, Brenner MK, Heslop HE. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr 1998;23:89-93.
28. Hopwood P, Crawford DH. The role of EBV in posttransplant malignancies: a review. J Clin Pathol 2000;53:248-254.
29. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:549-1555.
30. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001;97:835-843.
31. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996;87:2918-2929.
32. Franken M, Estabrooks A, Cavacini L, Sherburne B, Wang F, Scadden DT. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas. Nat Med 1996;2:1379-1382.
33. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000;60:5781-5788.
34. Robertson KD, Barletta J, Samid D, Ambinder RF. Pharmacologic activation of expression of immunodominant viral antigens: a new strategy for the treatment of Epstein-Barr-virus-associated malignancies. Curr Top Microbiol Immunol 1995;194:145-154.
35. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000;97:6055-6060.
36. Piche A, Kasono K, Johanning F, Curiel TJ, Curiel DT. Phenotypic knock-out of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther 1998;5:1171-1179.
37. Slobod KS, Taylor GH, Sandlund JT, Furth P, Helton KJ, Sixbey JW. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000;356:1493-1494.
38. Delecluse HJ, Hammerschmidt W. The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy. Mol Pathol 2000;53:270-279.
39. Jackman WT, Mann KA, Hoffmann HJ, Spaete RR. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 1999;17:660-668.